<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the management of the child or adolescent at risk for atherosclerosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the management of the child or adolescent at risk for atherosclerosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the management of the child or adolescent at risk for atherosclerosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarah D de Ferranti, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jacob C Hartz, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David R Fulton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Atherosclerotic vascular changes can begin in early childhood, setting the stage for atherosclerotic cardiovascular disease (ASCVD) events in adulthood. For most children, atherosclerotic vascular changes can be minimized or even prevented with adherence to a healthy lifestyle. However, in some children, the atherosclerotic process is accelerated because of the presence of identifiable risk factors  (<a class="graphic graphic_table graphicRef109927" href="/d/graphic/109927.html" rel="external">table 1</a>). The early identification of children and adolescents with these risk factors allows for timely interventions targeting modifiable risk factors to slow the atherosclerotic process and thereby potentially prevent or delay ASCVD.</p><p>An overview of the management of the child or adolescent at risk for atherosclerosis will be presented here. Related topics include:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16975.html" rel="external">"Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5781.html" rel="external">"Overview of risk factors for development of atherosclerosis and early cardiovascular disease in childhood"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16972.html" rel="external">"Dyslipidemia in children and adolescents: Definition, screening, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/121831.html" rel="external">"Familial hypercholesterolemia in children"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">RATIONALE FOR INTERVENTION</span><span class="headingEndMark"> — </span>Large, prospective, population-based, randomized controlled trial studies in adults demonstrate that reducing risk factors associated with atherosclerotic cardiovascular disease (ASCVD) decreases the occurrence of future ASCVD events. (See  <a class="medical medical_review" href="/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease", section on 'Established risk factors for atherosclerotic CVD'</a>.)</p><p>Similar long-term outcome data based on randomized clinical trials are not available for the pediatric population. However, prospective observational studies link the development of early-onset ASCVD risk factors to premature atherosclerotic changes in children. Furthermore, ASCVD risk factors track from childhood to adulthood. (See  <a class="medical medical_review" href="/d/html/5781.html" rel="external">"Overview of risk factors for development of atherosclerosis and early cardiovascular disease in childhood", section on 'Atherosclerotic changes in childhood'</a>.)</p><p>Short-term randomized controlled trials in children have demonstrated that lifestyle interventions and pharmacotherapy can successfully impact ASCVD risk factors (eg, dyslipidemia) in high-risk pediatric populations. These data are discussed separately. (See  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management", section on 'Dietary modification'</a> and  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management", section on 'Statin therapy'</a> and  <a class="medical medical_review" href="/d/html/121831.html" rel="external">"Familial hypercholesterolemia in children", section on 'Benefits of statin therapy'</a>.)</p><p>Based on the evidence from adult studies and the limited pediatric data, it is reasonable to assume that timely interventions to decrease or eliminate ASCVD risk factors during childhood can potentially slow the atherosclerotic process and thereby prevent or delay the onset of ASCVD [<a href="#rid1">1-4</a>].</p><p class="headingAnchor" id="H1443579335"><span class="h1">MANAGEMENT OF INDIVIDUAL RISK FACTORS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Modifiable risk factors and health behaviors</strong> – Modifiable ASCVD risk factors and health behaviors that may present during childhood and adolescence include the following  (<a class="graphic graphic_table graphicRef109927" href="/d/graphic/109927.html" rel="external">table 1</a>) [<a href="#rid3">3,4</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dyslipidemia (see <a class="local">'Dyslipidemia'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>Hypertension (see <a class="local">'Hypertension'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>Insulin resistance and diabetes mellitus (see <a class="local">'Insulin resistance and diabetes mellitus'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>Obesity (see <a class="local">'Obesity'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>Smoking cigarettes and other <a class="drug drug_general" data-topicid="9698" href="/d/drug information/9698.html" rel="external">nicotine</a> exposures (see <a class="local">'Smoking and nicotine exposure'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>Physical inactivity (see <a class="local">'Activity and inactivity'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>Disordered sleep (see <a class="local">'Healthy sleep habits'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other conditions</strong> – In addition to the health behaviors and traditional ASCVD risk factors listed above, other specific conditions are associated with accelerated atherosclerosis and premature ASCVD. These conditions are summarized in the table and are discussed in greater detail separately  (<a class="graphic graphic_table graphicRef109927" href="/d/graphic/109927.html" rel="external">table 1</a>) [<a href="#rid3">3,4</a>]. (See  <a class="medical medical_review" href="/d/html/5781.html" rel="external">"Overview of risk factors for development of atherosclerosis and early cardiovascular disease in childhood", section on 'Other conditions'</a>.):</p><p></p><p class="bulletIndent1">For children with one of these conditions, heightened awareness and evaluation for concurrent ASCVD risk factors are warranted. Similar to adults, in whom multiple risk factors are considered in the evaluation of risk for ASCVD, each of the additional risk factors described below are considered when making treatment decisions  (<a class="graphic graphic_algorithm graphicRef54963" href="/d/graphic/54963.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1">Management of these patients should include treatment of both the underlying primary disease and any comorbid ASCVD risk factors. The decision to initiate treatment and the type of intervention depend upon the individual’s risk of ASCVD risk, based upon their underlying disease and whether they have comorbid conditions (eg, hypertension, dyslipidemia, obesity). (See  <a class="medical medical_review" href="/d/html/5781.html" rel="external">"Overview of risk factors for development of atherosclerosis and early cardiovascular disease in childhood"</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Dyslipidemia</span><span class="headingEndMark"> — </span>Dyslipidemias are disorders of lipoprotein metabolism defined by abnormalities in the lipid profile  (<a class="graphic graphic_table graphicRef68183" href="/d/graphic/68183.html" rel="external">table 2</a>) [<a href="#rid4">4</a>]. The rationale for initiating therapy to control lipid disorders in children and adolescents is based upon increasing evidence that pediatric dyslipidemia (particularly elevated low-density lipoprotein cholesterol) contributes to early development of ASCVD.</p><p>Lipid screening in children  (<a class="graphic graphic_algorithm graphicRef105367 graphicRef121848" href="/d/graphic/105367.html" rel="external">algorithm 2A-B</a>) and the management of pediatric dyslipidemias  (<a class="graphic graphic_algorithm graphicRef106010" href="/d/graphic/106010.html" rel="external">algorithm 3</a>) are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/16972.html" rel="external">"Dyslipidemia in children and adolescents: Definition, screening, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Hypertension</span><span class="headingEndMark"> — </span>Hypertension in children is defined based on the normative distribution of blood pressure (BP) in healthy children  (<a class="graphic graphic_table graphicRef114574" href="/d/graphic/114574.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef63856" href="/d/graphic/63856.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef52646" href="/d/graphic/52646.html" rel="external">table 5</a>). The diagnosis of hypertension is based on repeated BP measurements separated over time. (See  <a class="medical medical_review" href="/d/html/6087.html" rel="external">"Definition and diagnosis of hypertension in children and adolescents"</a>.)</p><p>Treatment for hypertension includes both nonpharmacologic and pharmacologic interventions. Management decisions are dependent upon the severity of hypertension, underlying cause, evidence of end-organ damage, and other ASCVD risk factors [<a href="#rid5">5</a>].</p><p>Although there is no direct evidence that initiating therapy to lower BP in children and adolescents with hypertension lowers the risk of subsequent ASCVD [<a href="#rid5">5,6</a>], indirect data suggest that hypertension in childhood and adolescence contributes to premature ASCVD [<a href="#rid7">7-9</a>]. </p><p>The treatment of hypertension in children and adolescents is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents"</a>.)</p><p class="headingAnchor" id="H3034756296"><span class="h2">Insulin resistance and diabetes mellitus</span><span class="headingEndMark"> — </span>Insulin resistance, hyperinsulinemia, and elevated blood glucose are associated with atherosclerotic cardiovascular disease (ASCVD). In addition, children with diabetes mellitus are at increased risk for other atherogenic risk factors such as hypertension and dyslipidemia.</p><p>Randomized trials in adults and adolescents with type 1 diabetes mellitus have established that poor glycemic control contributes to long-term vascular sequelae. In addition, adult and adolescent clinical trials demonstrate that intensive insulin therapy, resulting in hemoglobin A1c levels &lt;7, decreases the risk of ASCVD. As a result, intensive glycemic control is recommended for children and adolescents with type 1 diabetes with age-specific goals for hemoglobin A1c levels. Similar recommendations are made for children with type 2 diabetes mellitus, particularly as these children are more commonly overweight, and some believe their ASCVD risk may be higher. (See  <a class="medical medical_review" href="/d/html/5817.html" rel="external">"Overview of the management of type 1 diabetes mellitus in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/5818.html" rel="external">"Complications and screening in children and adolescents with type 1 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/5821.html" rel="external">"Management of type 2 diabetes mellitus in children and adolescents"</a>.)</p><p>Children with type 1 or type 2 diabetes should undergo regular screening for dyslipidemia and should have BP measured at each medical encounter [<a href="#rid4">4,5,10</a>]. (See  <a class="medical medical_review" href="/d/html/5818.html" rel="external">"Complications and screening in children and adolescents with type 1 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/5826.html" rel="external">"Chronic complications and screening in children and adolescents with type 2 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Obesity</span><span class="headingEndMark"> — </span>Obesity, particularly central adiposity, is associated with accelerated atherosclerosis in childhood and increased risk of ASCVD in adulthood. Treatment for obesity in childhood can be challenging and it involves lifestyle changes at many levels. A multidisciplinary approach is encouraged, involving nutritional modification, behavioral counseling, and increased physical activity. The targeted body mass index (BMI) is ideally less than the 85<sup>th</sup> percentile for age and sex. These issues are addressed in separate topic reviews. (See  <a class="medical medical_review" href="/d/html/15848.html" rel="external">"Prevention and management of childhood obesity in the primary care setting"</a> and  <a class="medical medical_review" href="/d/html/5861.html" rel="external">"Clinical evaluation of the child or adolescent with obesity"</a> and  <a class="medical medical_review" href="/d/html/5869.html" rel="external">"Overview of the health consequences of obesity in children and adolescents"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Smoking and nicotine exposure</span><span class="headingEndMark"> — </span>Because smoke exposure, including secondhand smoke, increases the risk of ASCVD, all patients and their close contacts who smoke should be counseled to quit smoking. A number of approaches, including behavioral therapy, <a class="drug drug_general" data-topicid="9698" href="/d/drug information/9698.html" rel="external">nicotine</a> replacement therapy, and other pharmacologic therapies, are available. These issues are discussed separately. (See  <a class="medical medical_review" href="/d/html/6359.html" rel="external">"Management of smoking and vaping cessation in adolescents"</a> and  <a class="medical medical_review" href="/d/html/6920.html" rel="external">"Behavioral approaches to smoking cessation"</a> and  <a class="medical medical_review" href="/d/html/6375.html" rel="external">"Secondhand smoke exposure: Effects in children"</a> and  <a class="medical medical_review" href="/d/html/6376.html" rel="external">"Control of secondhand smoke exposure", section on 'Pediatrics'</a> and  <a class="medical medical_review" href="/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Activity and inactivity</span><span class="headingEndMark"> — </span>Evidence from both adult and pediatric studies demonstrates that daily vigorous activity and reduction in sedentary behavior improves cardiovascular health and decreases the risk of ASCVD in adulthood. The American Academy of Pediatrics and the National Heart, Lung, and Blood Institute expert panels recommend age-based daily activity for all children as summarized in the table  (<a class="graphic graphic_table graphicRef75748" href="/d/graphic/75748.html" rel="external">table 6</a>) [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/16975.html" rel="external">"Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children", section on 'Physical activity'</a>.)</p><p>In children with low levels of physical activity, we generally start at a lower intensity and frequency, moving to the ultimate goal of at least 60 minutes of moderate to vigorous physical activity for at least five days a week. The exercise regimen is increased gradually week by week to avoid setting unattainable goals. Directions on the expected exercise goals should be specific and clear to both the patient and parents/caregivers.</p><p>We also suggest limiting inactivity in the form of recreational screen time (eg, computer, video games, television) to ≤2 hours per day.</p><p>Physical activity and cardiovascular health in children and adults are discussed separately. (See  <a class="medical medical_review" href="/d/html/16975.html" rel="external">"Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children", section on 'Physical activity'</a> and  <a class="medical medical_review" href="/d/html/1510.html" rel="external">"Exercise and fitness in the prevention of atherosclerotic cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H3664026736"><span class="h2">Healthy sleep habits</span><span class="headingEndMark"> — </span>In adults, abnormal sleep duration (both too little and too much) and sleep disordered breathing (eg, obstructive sleep apnea) have been linked to increased risk of ASCVD. These associations are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7715.html" rel="external">"Insufficient sleep: Definition, epidemiology, and adverse outcomes", section on 'Cardiovascular morbidity'</a> and  <a class="medical medical_review" href="/d/html/7705.html" rel="external">"Obstructive sleep apnea and cardiovascular disease in adults"</a>.) </p><p>There are fewer data establishing a link between sleep problems in childhood and risk of premature ASCVD. Nevertheless, we emphasize the importance of establishing healthy sleep habits  (<a class="graphic graphic_table graphicRef52760 graphicRef120097" href="/d/graphic/52760.html" rel="external">table 7A-B</a>), including appropriate duration of sleep  (<a class="graphic graphic_figure graphicRef106597" href="/d/graphic/106597.html" rel="external">figure 1</a>), as part of a heart-healthy lifestyle. (See  <a class="medical medical_review" href="/d/html/6357.html" rel="external">"Assessment of sleep disorders in children"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">OVERALL APPROACH TO MANAGEMENT</span><span class="headingEndMark"> — </span>Management decisions for children and adolescents with risk factors for premature atherosclerotic cardiovascular disease (ASCVD) depend upon the nature of the risk factor(s), the clinical setting, and the values and preference of patients and their families/caregivers. Ideally, decisions to initiate therapy to reduce ASCVD risk would be based upon the child’s estimated risk. Although risk calculators are available to estimate 10-year ASCVD risk for adult patients, similar tools are not available for children.</p><p>Thus, the decision to intervene in children is largely dependent on the number and nature of ASCVD risk factors.</p><p>Our management approach is as follows and is consistent with published guidelines  (<a class="graphic graphic_algorithm graphicRef54963" href="/d/graphic/54963.html" rel="external">algorithm 1</a>) [<a href="#rid4">4,5</a>]. Therapy includes the following nonpharmacologic and pharmacologic interventions.</p><p class="bulletIndent1"><span class="glyph">●</span>Counseling for weight reduction in patients who are overweight or obese, including counseling on dietary changes and physical activity. (See  <a class="medical medical_review" href="/d/html/15848.html" rel="external">"Prevention and management of childhood obesity in the primary care setting"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Promoting a heart-healthy diet rich in vegetables, fruits, and whole grains; low in saturated fat; and devoid of trans fats  (<a class="graphic graphic_table graphicRef79084" href="/d/graphic/79084.html" rel="external">table 8</a>). (See  <a class="medical medical_review" href="/d/html/2866.html" rel="external">"Dietary recommendations for toddlers and preschool and school-age children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Counseling to foster increased activity to an ultimate goal of at least 60 minutes of moderate to vigorous physical activity for most days of the week and limiting screen time (eg, computer and television) to less than two hours a day  (<a class="graphic graphic_table graphicRef75748" href="/d/graphic/75748.html" rel="external">table 6</a>). (See <a class="local">'Activity and inactivity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Counseling for smoking cessation for patients or household members who smoke, prevention of secondhand smoke exposure, and avoidance of initiation of <a class="drug drug_general" data-topicid="9698" href="/d/drug information/9698.html" rel="external">nicotine</a> use. (See  <a class="medical medical_review" href="/d/html/6359.html" rel="external">"Management of smoking and vaping cessation in adolescents"</a> and  <a class="medical medical_review" href="/d/html/6376.html" rel="external">"Control of secondhand smoke exposure", section on 'Pediatrics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening for dyslipidemia  (<a class="graphic graphic_algorithm graphicRef105367 graphicRef121848" href="/d/graphic/105367.html" rel="external">algorithm 2A-B</a>), and initiating treatment, if appropriate  (<a class="graphic graphic_algorithm graphicRef106010" href="/d/graphic/106010.html" rel="external">algorithm 3</a>). (See  <a class="medical medical_review" href="/d/html/16972.html" rel="external">"Dyslipidemia in children and adolescents: Definition, screening, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening for hypertension and initiating treatment, if appropriate. (See  <a class="medical medical_review" href="/d/html/6087.html" rel="external">"Definition and diagnosis of hypertension in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with type 1 or type 2 diabetes mellitus, targeting age-appropriate goals for hemoglobin A1c levels (&lt;7 percent in most cases). (See  <a class="medical medical_review" href="/d/html/5817.html" rel="external">"Overview of the management of type 1 diabetes mellitus in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/5821.html" rel="external">"Management of type 2 diabetes mellitus in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with other underlying conditions that are associated with an increased risk of ASCVD  (<a class="graphic graphic_table graphicRef109927" href="/d/graphic/109927.html" rel="external">table 1</a>), treatment of the primary disease. (See  <a class="medical medical_review" href="/d/html/5781.html" rel="external">"Overview of risk factors for development of atherosclerosis and early cardiovascular disease in childhood", section on 'Other conditions'</a>.)</p><p></p><p class="headingAnchor" id="H1364320405"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110734.html" rel="external">"Society guideline links: Lipid disorders and atherosclerosis in children"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale</strong> – The rationale for treating children who are at risk for atherosclerosis is to delay the onset of the atherosclerotic process and, by extension, prevent or delay onset of atherosclerotic cardiovascular disease (ASCVD) in adult. This practice is based on evidence from large adult studies and more limited pediatric data that demonstrate an association between premature atherosclerosis and modifiable ASCVD risk factors. (See <a class="local">'Rationale for intervention'</a> above and  <a class="medical medical_review" href="/d/html/5781.html" rel="external">"Overview of risk factors for development of atherosclerosis and early cardiovascular disease in childhood"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for ASCVD</strong> – Modifiable ASCVD risk factors and health behaviors that may present during childhood and adolescence include the following  (<a class="graphic graphic_table graphicRef109927" href="/d/graphic/109927.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dyslipidemia (see <a class="local">'Dyslipidemia'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Hypertension (see <a class="local">'Hypertension'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Insulin resistance and diabetes mellitus (see <a class="local">'Insulin resistance and diabetes mellitus'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Obesity (see <a class="local">'Obesity'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Smoking cigarettes and other <a class="drug drug_general" data-topicid="9698" href="/d/drug information/9698.html" rel="external">nicotine</a> exposures (see <a class="local">'Smoking and nicotine exposure'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Physical inactivity (see <a class="local">'Activity and inactivity'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Disordered sleep (see <a class="local">'Healthy sleep habits'</a> above) </p><p></p><p class="bulletIndent1">In addition, other specific conditions are associated with accelerated atherosclerosis and premature ASCVD. These conditions are summarized in the table and are discussed in greater detail separately  (<a class="graphic graphic_table graphicRef109927" href="/d/graphic/109927.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/5781.html" rel="external">"Overview of risk factors for development of atherosclerosis and early cardiovascular disease in childhood", section on 'Other conditions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General management approach</strong> – Our management approach for children and adolescents with risk factors for premature ASCVD includes all of the following components  (<a class="graphic graphic_algorithm graphicRef54963" href="/d/graphic/54963.html" rel="external">algorithm 1</a>), which are discussed in detail separately (see <a class="local">'Overall approach to management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Counseling for weight reduction in patients with obesity, including dietary changes and increased physical activity. (See  <a class="medical medical_review" href="/d/html/15848.html" rel="external">"Prevention and management of childhood obesity in the primary care setting"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Promoting a heart-healthy diet rich in vegetables, fruits, and whole grains; low in saturated fat; and devoid of trans fats  (<a class="graphic graphic_table graphicRef79084" href="/d/graphic/79084.html" rel="external">table 8</a>). (See  <a class="medical medical_review" href="/d/html/2866.html" rel="external">"Dietary recommendations for toddlers and preschool and school-age children"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Counseling to increase physical activity  (<a class="graphic graphic_table graphicRef75748" href="/d/graphic/75748.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/d/html/16975.html" rel="external">"Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children", section on 'Physical activity'</a> and  <a class="medical medical_review" href="/d/html/1510.html" rel="external">"Exercise and fitness in the prevention of atherosclerotic cardiovascular disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Counseling for smoking cessation for patients or household members who smoke, prevention of secondhand smoke exposure, and avoidance of initiation of <a class="drug drug_general" data-topicid="9698" href="/d/drug information/9698.html" rel="external">nicotine</a> use. (See  <a class="medical medical_review" href="/d/html/6359.html" rel="external">"Management of smoking and vaping cessation in adolescents"</a> and  <a class="medical medical_review" href="/d/html/6376.html" rel="external">"Control of secondhand smoke exposure", section on 'Pediatrics'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Screening for dyslipidemia  (<a class="graphic graphic_algorithm graphicRef105367 graphicRef121848" href="/d/graphic/105367.html" rel="external">algorithm 2A-B</a>), and initiating treatment, if appropriate  (<a class="graphic graphic_algorithm graphicRef106010" href="/d/graphic/106010.html" rel="external">algorithm 3</a>). (See  <a class="medical medical_review" href="/d/html/16972.html" rel="external">"Dyslipidemia in children and adolescents: Definition, screening, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Screening for hypertension and initiating treatment, if appropriate. (See  <a class="medical medical_review" href="/d/html/6087.html" rel="external">"Definition and diagnosis of hypertension in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with type 1 or type 2 diabetes mellitus, targeting age-appropriate goals for hemoglobin A1c levels (&lt;7 percent in most cases). (See  <a class="medical medical_review" href="/d/html/5817.html" rel="external">"Overview of the management of type 1 diabetes mellitus in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/5821.html" rel="external">"Management of type 2 diabetes mellitus in children and adolescents"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with other underlying conditions that are associated with an increased risk of ASCVD  (<a class="graphic graphic_table graphicRef109927" href="/d/graphic/109927.html" rel="external">table 1</a>), treatment of the primary disease. (See  <a class="medical medical_review" href="/d/html/5781.html" rel="external">"Overview of risk factors for development of atherosclerosis and early cardiovascular disease in childhood", section on 'Other conditions'</a>.)</p><p></p><p class="headingAnchor" id="H3253987890"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jane Newburger, MD, MPH, and Michael Mendelson, MD, ScM, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">American Academy of Pediatrics. Cardiovascular risk reduction in high-risk pediatric populations. Pediatrics 2007; 119:618.</a></li><li><a class="nounderline abstract_t">McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007; 115:1948.</a></li><li><a class="nounderline abstract_t">de Ferranti SD, Steinberger J, Ameduri R, et al. Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association. Circulation 2019; 139:e603.</a></li><li><a class="nounderline abstract_t">Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 Suppl 5:S213.</a></li><li><a class="nounderline abstract_t">Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2017; 140.</a></li><li><a class="nounderline abstract_t">Thompson M, Dana T, Bougatsos C, et al. Screening for hypertension in children and adolescents to prevent cardiovascular disease. Pediatrics 2013; 131:490.</a></li><li><a class="nounderline abstract_t">Franks PW, Hanson RL, Knowler WC, et al. Childhood obesity, other cardiovascular risk factors, and premature death. N Engl J Med 2010; 362:485.</a></li><li><a class="nounderline abstract_t">Sundström J, Neovius M, Tynelius P, Rasmussen F. Association of blood pressure in late adolescence with subsequent mortality: cohort study of Swedish male conscripts. BMJ 2011; 342:d643.</a></li><li><a class="nounderline abstract_t">Gray L, Lee IM, Sesso HD, Batty GD. Blood pressure in early adulthood, hypertension in middle age, and future cardiovascular disease mortality: HAHS (Harvard Alumni Health Study). J Am Coll Cardiol 2011; 58:2396.</a></li><li><a class="nounderline abstract_t">American Diabetes Association. Management of dyslipidemia in children and adolescents with diabetes. Diabetes Care 2003; 26:2194.</a></li></ol></div><div id="topicVersionRevision">Topic 5753 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17332217" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cardiovascular risk reduction in high-risk pediatric populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17377073" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30798614" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22084329" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28827377" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23439904" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Screening for hypertension in children and adolescents to prevent cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20147714" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Childhood obesity, other cardiovascular risk factors, and premature death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21343202" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Association of blood pressure in late adolescence with subsequent mortality: cohort study of Swedish male conscripts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22115646" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Blood pressure in early adulthood, hypertension in middle age, and future cardiovascular disease mortality: HAHS (Harvard Alumni Health Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12832334" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Management of dyslipidemia in children and adolescents with diabetes.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
